This is a Phase I, single center, randomized, double-blind, placebo-controlled single ascending oral dose study to assess the safety, tolerability and pharmacokinetics of AZD7268 in healthy Japanese subjects.

Inclusion Criteria:

• Healthy Japanese male and female (of non-child bearing potential) subjects 20 to 45 years of age, inclusive

• Body weight between 50 and 90 kg, inclusive, with a Body Mass Index (BMI)

  • 18 to ≤ 27 kg/m2

Exclusion Criteria:

• Clinically relevant disease or disorder (past or present), which in the opinion of the investigator, may either put the subject at risk because of participation in the study or influence the results or the subject's ability to participate in the study
• Any clinically significant abnormalities in physical examination, vital signs, clinical chemistry, hematology or urinalysis results as judged by the investigator and/or sponsor
• Smoking in excess of 5 cigarettes per day or equivalent within 30 days of Day 1